Chinanews client, Beijing, February 3 (Reporter Zhang Ni) The reporter learned from the National Medical Insurance Administration that all provinces across the country formed an alliance to carry out the fourth batch of nationally organized drug centralized procurement, and the results of the proposed selection were produced in Shanghai on February 3. After the announcement, the official selection result will be released.

A total of 45 drugs were included in this purchase, all of which were successfully purchased, and the average price of the drugs to be selected was reduced by 52%.

Data map: The patient uses the face recognition system to make an appointment with an expert number under guidance.

Photo by Wang Guangzhao

　　According to reports, this centralized procurement adheres to the basic principle of "quantity and price linkage, integration of recruitment and procurement" and the working mechanism of "national organization, alliance procurement, and platform operation".

Adhere to high-quality standards, and still pass the quality and efficacy consistency evaluation as a condition for the entry of generic drugs.

At the same time, further fine-tuning and optimizing the procurement rules, the maximum number of selected companies will be increased from the original 8 to 10, and the supply guarantee capability will be improved.

　　A total of 152 companies participated in this centralized procurement, resulting in 118 companies to be selected. The percentage of companies to be selected increased to 71%. There were 158 products to be selected, including 5 products of 5 foreign-funded companies, involving Germany, France, India and Japan. Multinational pharmaceutical companies.

　　Among the products to be selected, products from listed companies, foreign-funded enterprises, top 100 companies and other companies account for 62%. At the same time, there are also two original drugs including amisulpride tablets and propofol medium/long-chain fat emulsion injections. The high-quality satisfaction of patients' medication needs reflects the stability of results after the normalization of procurement, and verifies the standardization of the working mechanism.

　　This purchase involves a variety of treatment fields such as hypertension, diabetes, gastrointestinal diseases, mental diseases, malignant tumors, etc. After this collection, the cost of a batch of commonly used drugs and anti-cancer drugs will be significantly reduced.

　　Taking the gastric ulcer treatment drug esomeprazole enteric-coated tablets (20mg/tablet) as an example, the price of each tablet dropped from 9 yuan to 3 yuan after the collection, and the entire treatment course can save about 240 yuan.

　　The price of a single tablet of the anticancer drug sorafenib has dropped from 95 yuan to 30 yuan. Based on the daily consumption of 2 tablets, it can save patients 3900 yuan per month.

　　The price of a single injection of bortezomib, an anticancer drug for the treatment of multiple myeloma, has been reduced from 1,500 yuan to 600 yuan, and the entire course of treatment can save about 36,000 yuan.

　　The schizophrenia treatment drug Amisulpride was selected by Sanofi, the original research drug company, and the price of a single tablet was reduced from 12 yuan to 1.6 yuan. Patients can save about 912 yuan per month.

　　It is expected that patients across the country will use the medicines after the price reduction of this centralized procurement in May 2021.

　　It is reported that in accordance with the requirements of the normalized and institutionalized centralized drug procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand to further ensure the demand for clinical drugs, ensure the quality and supply of drugs, and improve the benefit of patients. (Finish)